You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 7,780,984

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 7,780,984

Title:	Methods and compositions for treating proliferative diseases
Abstract:	The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s):	Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA), De; Tapas K. (Los Angeles, CA)
Assignee:	Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:	11/880,314
Patent Claims:	1. A method of treating a cancer disease in an individual, comprising administering to the individual an effective amount of a composition comprising nanoparticles comprising 17-AAG and an albumin, wherein the nanoparticles comprise 17-AAG coated with the albumin. 2. The method according to claim 1, wherein the cancer is lung cancer. 3. The method according to claim 1, wherein the 17-AAG is administered intravenously. 4. The method according to claim 1, wherein the albumin is human serum albumin. 5. The method according to claim 1, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm. 6. The method according to claim 1, wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1. 7. The method according to claim 4, wherein the average diameter of the nanoparticles in the composition is no greater than 200 nm. 8. The method according to claim 7, wherein the weight ratio of the albumin to 17-AAG in the composition is less than 18:1. 9. The method according to claim 1, wherein the composition does not induce significant side effects. 10. The method according to claim 5, wherein the average diameter of the nanoparticles in the composition is no greater than 100 nm. 11. The method according to claim 6, wherein the weight ratio of the albumin to 17-AAG in the composition is about 3:1 to about 12:1.

Details for Patent 7,780,984

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Grifols Therapeutics Llc	ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5	albumin (human)	For Injection	101138	10/21/1942	⤷ Try a Trial	2025-02-18
Baxalta Us Inc.	BUMINATE, FLEXBUMIN	albumin (human)	Injection	101452	03/03/1954	⤷ Try a Trial	2025-02-18
Csl Behring Ag	ALBURX	albumin (human)	Injection	102366	07/23/1976	⤷ Try a Trial	2025-02-18
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.